MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530316 | Name: FK960

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FK-960, also known as FK-59960, is a drug potentially for the treatment of Alzheimer's disease (AD). FK962 is also a novel enhancer of somatostatin release, which exerts cognitive-enhancing actions in rats. FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. FK960 ameliorates the memory deficits in rats through a novel mechanism of action.

Chemical Structure

FK960
CAS#133920-70-4 (free)

Theoretical Analysis

MedKoo Cat#: 530316

Name: FK960

CAS#: 133920-70-4 (free)

Chemical Formula: C13H16FN3O2

Exact Mass: 265.1227

Molecular Weight: 265.29

Elemental Analysis: C, 58.86; H, 6.08; F, 7.16; N, 15.84; O, 12.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
133920-70-4 (free) 208186-69-0 (hydrate)
Synonym
FK-960; FK960; FK960; FK-59960; FK 59960; FK59960.
IUPAC/Chemical Name
N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide
InChi Key
XTOKQKWTUYYVAO-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19)
SMILES Code
O=C(NN1CCN(C(C)=O)CC1)C2=CC=C(F)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 133920-70-4 (FK-960 Free) 208186-69-0 (FK-960 hydrate)

Preparing Stock Solutions

The following data is based on the product molecular weight 265.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, Mutoh S. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20. PubMed PMID: 16325809. 2: Koyama Y, Egawa H, Osakada M, Baba A, Matsuda T. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes. Biochem Pharmacol. 2004 Jul 15;68(2):275-82. PubMed PMID: 15193999. 3: Doggrell SA. The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin Investig Drugs. 2004 Jan;13(1):69-72. Review. PubMed PMID: 14680454. 4: Wang F, Matsuoka N, Mutoh S, Kaneko S. Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons. J Pharmacol Exp Ther. 2004 Jan;308(1):120-6. PubMed PMID: 14569070. 5: Noda A, Takamatsu H, Matsuoka N, Koyama S, Tsukada H, Nishimura S. Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), an antidementia drug with a novel mechanism of action, on regional cerebral blood flow and glucose metabolism in aged rhesus macaques studied with positron emission tomography. J Pharmacol Exp Ther. 2003 Jul;306(1):213-7. PubMed PMID: 12676883. 6: Tada H, Uchino M, Nagai K, Nomura T, Kondoh T, Saito N, Yamamura T, Yajima Y, Nishizaki T. The anti-dementia drug FK960 stimulates glial glutamate release via a PKA pathway. Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):63-8. PubMed PMID: 12531516. 7: Noda A, Takamatsu H, Murakami Y, Yajima K, Tatsumi M, Ichise R, Nishimura S. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J Nucl Med. 2003 Jan;44(1):105-8. PubMed PMID: 12515883. 8: Moriguchi A, Nakano K, Yamaguchi I, Sano K, Noda K, Hashimoto M, Ohara K, Matsuoka N, Goto T. FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. Brain Res. 2002 Dec 27;958(2):381-9. PubMed PMID: 12470874. 9: Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav. 2002 Oct;73(3):511-9. PubMed PMID: 12151024. 10: Tozaki H, Kanno T, Nomura T, Kondoh T, Kodama N, Saito N, Aihara H, Nagata T, Matsumoto S, Ohta K, Nagai K, Yajima Y, Nishizaki T. Role of glial glutamate transporters in the facilitatory action of FK960 on hippocampal neurotransmission. Brain Res Mol Brain Res. 2001 Dec 16;97(1):7-12. PubMed PMID: 11744157. 11: Hodgkiss JP, Kelly JS. Effect of FK960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus. J Pharmacol Exp Ther. 2001 May;297(2):620-8. PubMed PMID: 11303051. 12: Inoue T, Wang F, Moriguchi A, Shirakawa K, Matsuoka N, Goto T. FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7. PubMed PMID: 11172755. 13: Matsuyama S, Nomura T, Nishizaki T. Sustained facilitatory action of FK960 on hippocampal neurotransmission. Brain Res. 2000 Feb 28;857(1-2):317-20. PubMed PMID: 10700585. 14: Tsukada H, Yamazaki S, Noda A, Inoue T, Matsuoka N, Kakiuchi T, Nishiyama S, Nishimura S. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, restores the regional cerebral blood flow response abolished by scopolamine but not by HA-966: a positron emission tomography study with unanesthetized rhesus monkeys. Brain Res. 1999 Jun 19;832(1-2):118-23. PubMed PMID: 10375657. 15: Matsuoka N, Satoh M. FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices. Brain Res. 1998 Jun 1;794(2):248-54. PubMed PMID: 9622644. 16: Matsuoka N, Aigner TG. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine. J Pharmacol Exp Ther. 1997 Mar;280(3):1201-9. PubMed PMID: 9067304. 17: Yamazaki M, Matsuoka N, Maeda N, Ohkubo Y, Yamaguchi I. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. J Pharmacol Exp Ther. 1996 Dec;279(3):1157-73. PubMed PMID: 8968337.

View History

Selgantolimod

Selgantolimod

Featured